hypophosphatemia%20-and-%20hyperphosphatemia
HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Hypophosphatemia%20-and-%20hyperphosphatemia Signs and Symptoms

Introduction

Hypophosphatemia is recognized most often in:
  • Critically-ill patients
  • Decompensated diabetics
  • Alcoholics or other malnourished persons
  • Acute infectious or pulmonary disorders
  • Patients who are in IV hyperalimentation without phosphate supplementation
  • Patients with urinary phosphate-wasting syndromes (eg Fanconi syndrome or tumor-induced osteomalacia)

Hyperphosphatemia

  • Defined as an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present

Etiology

Hypophosphatemia 

  • More pronounced when there is underlying phosphate depletion (eg hyperparathyroidism,vitamin D deficiency, alcoholism and glycosuria)
  • Mechanisms that may cause hypophosphatemia:
    • Increased urinary losses due to impaired intestinal absorption
    • Redistribution of phosphate from extracellular fluid into the intracellular space or the mineral phase of bone
    • Removal by renal replacement therapies
    • Severe and selective deprivation of dietary phosphate that rarely occurs

Hyperphosphatemia

  • Decreased Renal Phosphate Excretion
    • Renal failure
    • Hypoparathyroidism
    • Pseudohypoparathyroidism
    • Familial tumoral calcinosis
    • Bisphosphonate therapy
    • Vitamin D intoxication
    • Acromegaly
    • Mg deficiency
  • Others
    • Acid-base disorders
    • Crush injuries
    • Fulminant hepatitis
    • Rhabdomyolysis
    • Artifactual due to hemolysis
    • Extracellular shift from intracellular compartment
    • Chronic Heparin therapy

Signs and Symptoms

Hypophosphatemia
Mild
  • Usually asymptomatic
Moderate-Severe
  • Neurological: Confusion, irritability, apprehension, fatigue, numbness, paresthesia, seizures, coma, metabolic encephalopathy
  • Musculoskeletal: Myalgia and myopathy, muscle weakness, rhabdomyolysis, rickets, osteomalacia
  • Respiratory: Reversible respiratory failure
  • Cardiovascular: Impairment of cardiac contractility, cardiomyopathy
  • Hematological: Hemolysis, thrombocytopenia, impaired phagocytosis
Hyperphosphatemia
Acute - 
Most symptoms are due to secondary hypocalcemia
  • Hypocalcemia
  • Neuromuscular irritability/muscle cramps
  • Tetany
  • Paresthesias
  • Seizures
  • Hypotension
  • Cardiac arrhythmia

Chronic - Persistent hyperphosphatemia (>12 hours) that usually occurs in patients with chronic renal failure and familial tumoral calcinosis

  • Normocalcemia
  • Nephrocalcinosis
  • Soft tissue or vascular calcification
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.